HOME >> BIOLOGY >> NEWS
Israeli scientists block the progression of Type I diabetes

Rehovot, Israel -- November 26, 2001--A team of researchers led by Prof. Irun Cohen of the Weizmann Institute of Science has developed a unique approach for halting the progression of Type I (juvenile or insulin-dependent) diabetes.

Cohen and Dr. Dana Elias (then a postdoctoral fellow at the Institute) discovered that injecting mice with a small peptide fragment known as p277 prevents the progression of Type I diabetes. Based on the results of his research, Peptor, a biopharmaceutical company from Rehovot, Israel, developed DiaPep277, an experimental drug designed to prevent or treat Type I diabetes.

A recent clinical study performed by researchers at Hadassah-Hebrew University Medical School and Peptor Ltd. proved that DiaPep277 is successful in arresting the progression of Type I diabetes in newly diagnosed patients. The research findings are published in the November 24, issue of The Lancet.

The study was of 35 patients newly diagnosed with Type I diabetes. Eighteen patients received injections of DiaPep277 at the beginning of the study, at one month, and at six months; 17 patients received three injections of an inert substance (placebo). Patients in the treatment group (those receiving DiaPep277) showed a halt or delay in the attack upon, or destruction of their pancreatic insulin-producing cells by the immune system. These results were evident in the level of the bodys own insulin production and in a decreased need for insulin injections. The researchers were able to trace the mechanism of this improvement to changes in the patients immune lymphocytes called T-cells. In contrast, patients receiving the placebo showed a significant decline in their natural insulin production and a persistent rise in the need for insulin injections. No significant side effects as a result of injecting DiaPep277 were found.

Diabetes is a chronic disease associated with elevated blood sugar levels, in which the body does not produce or properly us
'"/>

Contact: Jeffrey Sussman
jeffrey@acwis.org
212-895-7951
American Committee for the Weizmann Institute of Science
22-Nov-2001


Page: 1 2

Related biology news :

1. Israeli scientists reveal the plan of a key cellular machine
2. Study by Israeli scientists provides insight on DNA code
3. Scientists identify a gene causing a fatal heart condition, common in an Israeli Bedouin tribe
4. Israeli scientists discover gene responsible for hereditary muscle disease prevalent among Jews of Persian descent
5. Israeli teams grows heart cells and insulin producing cells from human embryonic stem cells
6. Israeli fertility experts call for international chromosome registry
7. Dr. Robert C. Gallo to Collaborate with Visiting Israeli Scientist on Promising HIV Vaccine Research at Marylands Institute of Human Virology
8. Researchers develop white wine with cholesterol-lowering benefits, discover Israeli wines healthier than French wines
9. Hopkins, Israeli Scientists Link Soybeans With Pain Relief
10. DNA lends scientists a hand, revealing new chemical reactions
11. Conference at UH opens doors for new scientists, engineers

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/31/2020)... ... July 30, 2020 , ... Justin Zamirowski to ... a near term focus on Type 2 diabetes and associated comorbidities. , Justin ... therapeutic areas and classes. As Chief Commercial Officer, Justin will lead Better ...
(Date:7/18/2020)... ... ... Commercial launch readiness is a critical stage in a product life cycle. ... the global economic downturn will only increase price pressures overall for the industry. The ... value from every product launch is critical. However, history shows that only a third ...
(Date:7/4/2020)... PHOENIX (PRWEB) , ... July 03, 2020 , ... ... is proud to earn outstanding recognition and multiple awards for not only the ... the ABM portfolio, SoME® Skincare and Vivace® Microneedle RF. All the brands built ...
Breaking Biology News(10 mins):
(Date:9/1/2020)... ... September 01, 2020 , ... ... biotechnology, and diagnostics companies, has announced the placement of Julianne Averill , ... responsible for leading all financial operations and implementing key business strategies to accelerate ...
(Date:8/12/2020)... ... August 11, 2020 , ... The FSHD Society ... Muscular Dystrophy Clinical Trial Research Network (FSHD CTRN), with consideration of ... a consortium of academic research centers in the United States and Europe with ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... Mass. (PRWEB) , ... July 29, 2020 , ... ... highly reliable, solid-state radar transmitter systems that can be configured to drive Klystrons, ... single controller that can drive one or two switches in a push-pull configuration; ...
Breaking Biology Technology:
Cached News: